Chemistry:Entinostat
From HandWiki
| Names | |
|---|---|
| Preferred IUPAC name
(Pyridin-3-yl)methyl ({4-[(2-aminophenyl)carbamoyl]phenyl}methyl)carbamate | |
| Other names
SNDX-275; MS-275
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| KEGG | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C21H20N4O3 | |
| Molar mass | 376.4085 g/mol |
| Pharmacology | |
| 1=ATC code }} | L01XH05 (WHO) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
Tracking categories (test):
Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers.[1]
Entinostat inhibits class I HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, respectively.[2]
Syndax pharmaceuticals currently holds the rights to entinostat and recently received $26.6 million in funds to advance treatments of resistant cancers using epigenetic tools.[3]
References
- ↑ Phase I trial of 5-azacitidine (5AC) and SNDX-275 in advanced lung cancer (NSCLC)
- ↑ Novel Sulphonylpyrroles as Inhibitors of Hdac S Novel Sulphonylpyrroles
- ↑ http://www.syndax.com/assets/130827%20Syndax%20Series%20B%20news%20release.pdf [bare URL PDF]
